The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Adalimumab (Brand name: Humira)
- Manufactured by
FDA-approved indication: October 2018, adalimunab (Humira) received expanded approval for the treatment of moderate to severe hidradenitis suppurativa (HS) to include patients 12 years and up. It was originally approved for adults with moderate to severe HS in September 2015.
National Library of Medicine Drug Information PortalMedline Plus Health Information